The synthetic data revolution in healthcare

Watch this webinar to hear speakers delve into the ethical considerations, strategies for mitigating risk, and the patient-centered outcomes that synthetic data brings to transform life sciences innovation.

This panel discussion was moderated by partners Edoardo Tedeschi and Lydia Torne, and you will hear from industry experts Raphaela Schnurbus, Senior Director of Business Development at Premier Research, Mario Torchia, COO at InSilicoTrials and Lucia Zaccardi, Senior R&D Medical Scientific Liaison Manager at IBSA Group regarding their respective experience using synthetic data in developing new medicines.

The discussion covered:

• The ethical benefits of synthetic data replacing or supplementing animal or human data in pre-clinical and clinical trials.
• The power of decentralised clinical trials to make drug development more patient-centric by bringing the trial to the patients' homes and the corresponding benefits for drug developers.
• The commercial benefits of using synthetic data, Modeling and Simulation (M&S) and digital twin technology to mitigate risk when developing new drug products.